Author:
Xu Xiaoling,Cheng Lei,Fan Yun,Mao Weimin
Reference42 articles.
1. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma. (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial;Alley;Lancet Oncol,2017
2. New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas;Mossman;Am J Pathol,2013
3. Tremelimumab combined with durvalumab in patients with mesothelioma. (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study;Calabro;Lancet Respir Med,2018
4. ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma;Scherpereel;Eur Respir J,2020
5. Inferring tumour purity and stromal and immune cell admixture from expression data;Yoshihara;Nat Commun,2013
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献